Stock Scorecard
Stock Summary for CASI Pharmaceuticals Inc (CASI) - $2.98 as of 12/30/2024 12:36:09 PM EST
Total Score
8 out of 30
Safety Score
14 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CASI
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CASI
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CASI
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CASI
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for CASI (14 out of 100)
Stock Price Rating (Max of 10) | 3 |
Historical Stock Price Rating (Max of 10) | 7 |
Stock Price Trend (Max of 10) | 1 |
Book Value (Max of 10) | 1 |
Book Value to Price (Max of 10) | 0 |
Analyst Buy Ratings (Max of 5) | 0 |
Analyst Strong Buy Ratings (Max of 5) | 0 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 0 |
Trading Volume (Max of 10) | 2 |
Price to Earnings (Max of 10) | 0 |
Latest News for for CASI
Financial Details for CASI
Company Overview |
|
---|---|
Ticker | CASI |
Company Name | CASI Pharmaceuticals Inc |
Country | China |
Description | CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and markets therapeutic and pharmaceutical products in China, the United States, and internationally. The company is headquartered in Rockville, Maryland. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 6/30/2024 |
Next Earnings Date | 3/26/2025 |
Stock Price History |
|
Last Day Price | 2.98 |
Price 4 Years Ago | 29.50 |
Last Day Price Updated | 12/30/2024 12:36:09 PM EST |
Last Day Volume | 49,484 |
Average Daily Volume | 53,131 |
52-Week High | 8.19 |
52-Week Low | 2.05 |
Last Price to 52 Week Low | 45.37% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 21.50 |
Sector PE | 40.21 |
5-Year Average PE | -3.51 |
Free Cash Flow Ratio | 2.79 |
Industry Free Cash Flow Ratio | 11.85 |
Sector Free Cash Flow Ratio | 27.17 |
Current Ratio Most Recent Quarter | 3.20 |
Total Cash Per Share | 1.07 |
Book Value Per Share Most Recent Quarter | 0.67 |
Price to Book Ratio | 3.44 |
Industry Price to Book Ratio | 4.95 |
Sector Price to Book Ratio | 20.56 |
Price to Sales Ratio Twelve Trailing Months | 2.06 |
Industry Price to Sales Ratio Twelve Trailing Months | 81.76 |
Sector Price to Sales Ratio Twelve Trailing Months | 24.58 |
Analyst Buy Ratings | N/A |
Analyst Strong Buy Ratings | N/A |
Share Statistics |
|
Total Shares Outstanding | 15,461,100 |
Market Capitalization | 46,074,078 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Current Dividend Amount | 0.00 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 31.65% |
Reported EPS 12 Trailing Months | -2.03 |
Reported EPS Past Year | -1.81 |
Reported EPS Prior Year | -2.02 |
Net Income Twelve Trailing Months | -30,349,000 |
Net Income Past Year | -26,938,000 |
Net Income Prior Year | -39,411,000 |
Quarterly Revenue Growth YOY | -59.50% |
5-Year Revenue Growth | 0.00% |
Operating Margin Twelve Trailing Months | -240.10% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 16,537,000 |
Total Cash Past Year | 17,083,000 |
Total Cash Prior Year | 47,112,000 |
Net Cash Position Most Recent Quarter | -1,928,000 |
Net Cash Position Past Year | -1,812,000 |
Long Term Debt Past Year | 18,895,000 |
Long Term Debt Prior Year | 466,000 |
Total Debt Most Recent Quarter | 18,465,000 |
Equity to Debt Ratio Past Year | 0.56 |
Equity to Debt Ratio Most Recent Quarter | 0.43 |
Total Stockholder Equity Past Year | 24,165,000 |
Total Stockholder Equity Prior Year | 44,574,000 |
Total Stockholder Equity Most Recent Quarter | 13,847,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | 0 |
Free Cash Flow Per Share Twelve Trailing Months | 0.00 |
Free Cash Flow Past Year | -22,208,000 |
Free Cash Flow Prior Year | -26,700,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | Options Chain |
Liquidity Rating | None |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.59 |
MACD Signal | -0.59 |
20-Day Bollinger Lower Band | 2.70 |
20-Day Bollinger Middle Band | 5.37 |
20-Day Bollinger Upper Band | 8.03 |
Beta | 0.65 |
RSI | 33.05 |
50-Day SMA | 4.87 |
150-Day SMA | 3.93 |
200-Day SMA | 6.43 |
System |
|
Modified | 12/27/2024 8:20:17 PM EST |